- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting | 7 | GlobeNewswire (USA) | ||
| 16.12. | Mink Therapeutics-Aktie erreicht 52-Wochen-Tief bei 0,56 US-Dollar | 1 | Investing.com Deutsch | ||
| 16.12. | Mink Therapeutics stock hits 52-week low at $0.56 amid market challenges | 1 | Investing.com | ||
| MINK THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 13.12. | Cellistic and BrightPath Bio: BrightPath Bio und Cellistic kündigen Zusammenarbeit bei Prozessentwicklung und Fertigung für klinische Phase-1-Studie mit iPSC-abgeleiteten BCMA CAR-iNKT-Zellen an | 364 | Business Wire | BrightPath Bio (Tokyo Stock Exchange Growth 4594, "BrightPath"), ein Pionier auf dem Gebiet der aus iPS-Zellen gewonnenen Natural-Killer-T-Zelltherapie ("NKT"), und Cellistic, ein führendes Unternehmen... ► Artikel lesen | |
| 13.12. | Cellistic and BrightPath Bio: BrightPath Bio and Cellistic Announces Process Development and Manufacturing Collaboration for Phase 1 Clinical Trial of iPSC-derived BCMA CAR-iNKT cell | 281 | Business Wire | BrightPath Bio (Tokyo Stock Exchange Growth 4594, "BrightPath"), a pioneer in iPS cell-derived Natural Killer T ("NKT") cell therapy, and Cellistic, a leader in advanced iPS cell therapy manufacturing... ► Artikel lesen | |
| 14.11. | MiNK Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.11. | Examining the Future: MiNK Therapeutics' Earnings Outlook | 2 | Benzinga.com | ||
| 11.11. | MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report | 5 | GlobeNewswire (USA) | ||
| 07.11. | MiNK Therapeutics: MiNK's iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024 | 77 | GlobeNewswire (Europe) | AgenT-797 Combination with Checkpoint Inhibitors and Bispecific Engagers Expands Anti-Cancer Benefit PRAME-TCR iNKT Overcomes Challenges from Conventional TCR-T Cells in Solid Cancers NEW YORK, Nov.... ► Artikel lesen | |
| 31.10. | MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors | 2 | GlobeNewswire (USA) | ||
| 31.10. | MiNK Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 18.10. | MiNK Therapeutics announces executive transition | 3 | Investing.com | ||
| 18.10. | MiNK Therapeutics, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 09.10. | MiNK Therapeutics stock gets boost from new RNA collaboration with Autonomous | 2 | Investing.com | ||
| 08.10. | MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors | 65 | GlobeNewswire (Europe) | NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics (MiNK, NASDAQ: INKT) a clinical-stage company pioneering the development of allogeneic off-the-shelf, invariant natural killer T (iNKT)... ► Artikel lesen | |
| 07.10. | Mink Therapeutics-Aktie erreicht 52-Wochen-Tief bei 0,71 US-Dollar | 1 | Investing.com Deutsch | ||
| 07.10. | Mink Therapeutics stock hits 52-week low at $0.71 amid market challenges | 1 | Investing.com | ||
| 04.10. | MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024 | 4 | GlobeNewswire (USA) | ||
| 13.09. | MiNK Therapeutics droht Delisting von der Nasdaq | 2 | Investing.com Deutsch | ||
| 13.09. | MiNK Therapeutics faces potential Nasdaq delisting | 2 | Investing.com |
Seite:
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,150 | +3,60 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,380 | +4,11 % | Defence Therapeutics Inc.: Defence Announces Molecular and Antibody Research Expert Dr. Elias Theodorou Joins Its Board of Directors | Vancouver, British Columbia--(Newsfile Corp. - December 20, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| GINKGO BIOWORKS | 9,700 | 0,00 % | Ginkgo Bioworks eligible for $9.4M in partnership for bioelectronic devices | ||
| RECURSION PHARMACEUTICALS | 6,035 | 0,00 % | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug... ► Artikel lesen | |
| BEAM THERAPEUTICS | 29,000 | 0,00 % | Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology ... | NHP Data Showed CD117 Monoclonal Antibody (mAb) Conditioning Successfully Achieved Long-term Engraftment of Base-edited Hematopoietic Stem Cells and Induced Robust Levels of Hemoglobin F mAb Dosing... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,730 | 0,00 % | Oncolytics Biotech (TSE:ONC) Stock Price Up 14.5% - Here's What Happened | ||
| ARCTURUS THERAPEUTICS | 15,500 | 0,00 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen | |
| ASSERTIO | 0,891 | 0,00 % | Assertio Holdings, Inc. - 8-K, Current Report | ||
| ADMA BIOLOGICS | 17,400 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility | ||
| SIGA TECHNOLOGIES | 5,930 | 0,00 % | SIGA Technologies Inc.: Interim Results from STOMP Study of SIGA's Tecovirimat in Treatment of Mpox Announced | Interim analysis shows that tecovirimat did not improve time to lesion resolution compared to placebo in adults with mild to moderate clade II mpoxStudy stopped enrolling patients in all study armsResults... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 7,340 | 0,00 % | Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2024.
"This quarter... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 16,400 | -0,61 % | Travere Therapeutics, Inc.: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on November 10, 2024, the Compensation Committee of its Board of Directors granted inducement... ► Artikel lesen | |
| VERVE THERAPEUTICS | 5,735 | 0,00 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on November 29,... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,895 | 0,00 % | Where Will Summit Therapeutics Be in 5 Years? | ||
| BIO-PATH | 1,260 | 0,00 % | Pre-market Movers: PainReform, CURRENC Group, Bio-Path Holdings, Abpro Corporation, KULR Technology | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.35 A.M. ET).In the Green PainReform Ltd. (PRFX) is up over... ► Artikel lesen |
MINK THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,524 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MINK THERAPEUTICS INC finden Sie auf Wallstreet Online.
